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We studied changes in apathy among 77 community-dwelling older persons with mild memory loss in a randomized clinical trial
comparing two nonpharmacological interventions over four weeks. The study used a pre-post design with randomization by site
to avoid contamination and diffusion of effect. Interventions were offered twice weekly after baseline evaluations were completed.
The treatment group received classroom style mentally stimulating activities (MSAs) while the control group received a structured
early-stage social support (SS) group. The results showed that the MSA group had significantly lower levels of apathy (P < .001)
and significantly lower symptoms of depression (P < .001). While both groups improved on quality of life, the MSA group was
significantly better (P = .02) than the SS group. Executive function was not significantly different for the two groups at four
weeks, but general cognition improved for the MSA group and declined slightly for the SS group which produced a significant
posttest difference (P < .001). Recruitment and retention of SS group members was difficult in this project, especially in senior
center locations, while this was not the case for the MSA group. The examination of the data at this four-week time point shows
promising results that the MSA intervention may provide a much needed method of reducing apathy and depressive symptoms,
while motivating participation and increasing quality of life.
1. Introduction
Neuropsychiatric symptoms of dementia are common and
associated with poor outcomes for patients and caregivers
[1]. Apathy is the most common neuropsychiatric symptom
in mild to moderate stages of Alzheimer’s disease (AD) and
increases in severity as the dementia progresses. Apathy is
complex to treat in AD since it is often mixed with other
challenging behaviors and confused with depression [2]. A
review of scientific evidence shows that pharmacological
therapies are not particularly effective for management of
these mixed symptoms and further complicated by danger-
ous side effects [3]. With an estimated 5.5 million Americans
with dementia, safe, effective, and easy to deliver therapies
are desperately needed for this problem [1, 3–5].
Apathy is defined as the loss of motivation not attributa-
ble to cognitive impairment, emotional distress, or reduced
level of consciousness [5]. Apathy occurs in approximately
70% of Alzheimer’s disease (AD) patients within five years
of diagnosis [6]. AD patients with apathy require more
management and support, given their reliance on others
to schedule their activities and initiate tasks even when
they are still physically capable of performing them. Studies
examining the relationship of apathy to neuropsychological
measures showed that apathy was consistently associated
with more severe functional impairments, more severe
cognitive deficits, higher levels of burden and distress in
caregivers, along with increased resource utilization [7, 8].
Apathy in early-stage AD is often overlooked by health-
care providers, yet if left untreated, leads to more rapid than
expected functional decline [9]. The etiology of apathy is
complex and thought to be related to underlying pathology,
atrophy of the frontal lobes, and their connections to the
temporal lobes [10]. Damage to these areas of the brain
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Figure 1: Theoretical model for apathy and the MSA intervention.
reduces the ability to initiate, sequence, and complete tasks.
Such losses can lead to unmet needs for cognitive, social,
emotional, and physical stimulation.
Older individuals with early-stage memory problems
have unmet needs with respect to stimulation, socialization,
needs for adaptation of tasks for successful performance, and
yet have a desire for novel mentally stimulating experiences
to maintain abilities [2, 11–16]. Research shows that patients
with Mild Cognitive Impairment (MCI) and early-stage AD
continue to respond well to stimulation, often performing
at the same levels of brain activity as age-matched controls
[17, 18]. While the current “state-of-the-art” intervention for
early-stage dementia is an early stage support group, those
with apathy may not attend or may not benefit in the same
way as more motivated participants.
Expanding on Marin’s Model of Apathy [19] (Figure 1),
we hypothesize that Mentally Stimulating Activities (MSAs)
that match current skill levels should be more effective in
engaging participants with apathy and early-stage memory
loss because they meet individual needs for stimulation
while leading to more focused and successful therapeutic
experiences. Further, when engaged in MSAs with others,
in classroom-style groups, positive emotions should increase
and pleasant experiences with others occur. Finally, the
physical performance that takes place in each MSA session
reduces motor apathy and provides game-like opportunities
for active engagement again. These three subcomponents
work together to reduce motor, cognitive, and emotional
apathy, allow for failure-free enhanced engagement with
others, and theoretically could help participants maintain
function and improve QOL. This randomized controlled
trial (RCT) offered participants either a course in classroom
style MSAs or a structured early-stage social support (SS)
group for symptoms of early-stage memory loss. This paper
will present the impact of a 2-arm RCT cognitive stimulation
intervention on apathy, depression, executive function, and
cognition in a subset of participants after 4 weeks of
intervention. The fully powered complete study will have 120
participants with repeated measures at baseline, four weeks,
eight weeks, and 12 weeks.
2. Methods
2.1. Study Design and Participants. The first 77 participants
randomized in the trial with pretest and 4-week posttest
scores are included in this paper. Randomization by site
(n = 8 sites) rather than by participant was used to control
for possible cross-contamination of treatment or diffusion
of effect. The participants to date were recruited from
Continuing Care Retirement Communities and local senior
centers in central North Carolina and met the following
inclusion criteria: English speaking; 60 years of age or older;
diagnosis of dementia or symptoms that meet DSM-IV [20]
criteria for probable early-stage AD or Peterson criteria for
MCI [21]; a Mini-Mental State Exam (MMSE) [22] score of
18 or greater but less than 28; stable on any psychoactive drug
from prebaseline through final observation to control for the
effect these drugs have on neuropsychiatric behavior; and
presence of apathy as reported by family, significant other,
or medical provider. Exclusion criteria included delirium or
a progressive, unstable medical, metabolic, or neurological
illness that might interfere with behavior; recent fracture
(within 4 months); history of Parkinson’s disease, Hunt-
ington’s disease, seizure disorder, major stroke, alcoholism,
drug abuse, recent head trauma with loss of consciousness,
or psychiatric illness preceding the onset of memory loss;
severe vision or hearing impairment; and receiving a new
psychoactive medication within the past 30 days. Participants
were screened for inclusion by a Geriatric Nurse Practitioner,
and for cases without cognitive diagnoses the study PI or
medical director was consulted before the participant was
included. The IRB of the University of North Carolina at
Greensboro provided human subjects approval and data
safety and monitoring for this study.
2.2. Mentally Stimulating Activity Program. The MSA pro-
gram was developed by Fitzsimmons [23, 24] and has been
used in community-based, hospital, and long-term care
settings by the first and second authors in clinical practice.
Specific cognitive tasks target attention, orientation, concen-
tration, short-term memory, and organized thinking in a
classroom style setting. In general, activities were designed to
be stimulating, challenging, novel, and fun but not frustrat-
ing. Each task takes from 2–10 minutes and is interactive and
goal driven. The one hour, twice weekly sessions included a
variety of physical and cognitive activities that rely on various
functions of the brain: visual spatial abilities, verbal and non-
verbal communication skills, abstract concepts, eye-hand
coordination, fine motor control, body orientation, crossing
the midline, recognition memory, short-and long-term
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Table 1: Participant demographics (values are presented as n (%) or mean (standard deviation)).
Total Control (social support) Treatment (mentally stimulating activities) P value
Participants (n) 77 29∗ 48
Gender .243
Male 15 (19.5%) 4 (13.8%) 11 (22.9%)
Female 62 (80.5%) 25 (86.2%) 36 (77.1%)
Race .071
Caucasian 56 (72.7%) 17 (58.6%) 39 (81.3%)
African-American 20 (25.9%) 11 (37.9%) 9 (18.7%)
Hispanic 1 (1.3%) 1 (.03%) 0 (0%)
Depression DX .594
Yes 20 7 (24.1%) 13 (27.1%)
No 57 22 (75.9%) 35 (72.9%)
Mean Age 82.2 (6.5) 81.0 (8.7) .07
Years of Education 13.6 (3.8) 14.6 (3.6) .499
Baselines
MMSE 25.4 (2.8) 25.2 (3.3) .269
AES (Apathy) 30.4 (7.9) 32.8 (8.7) .331
Cornell-Brown 18.6 (11.3) 14.3 (10.8) .758
PHQ-9 4.7 (4.8) 5.9 (5.7) .188
Trail Making Time 192.80 (89.7) 178.45 (90.0) .635
∗
48 participants were enrolled but 19 dropped after baseline recruitment and evaluation due to health problems and lack of interest in the intervention (39%).
These participants were not included in the pre-post analysis.
memory, executive functioning, and sensory identification.
The facilitated tasks were performed by participants alone,
in pairs, or as a group. Participants were encouraged to find
alternate methods to complete the tasks and were encouraged
to help each other.
2.3. Structured Early-Stage Social Support Program. The SS
program was developed as a structured psychoeducational
group with information about brain health, group discus-
sion, and emotional support provided during each session.
The trained facilitator provided the structure and led
the discussion. Group members were encouraged to share
frustrations, concerns, and thoughts on dealing with the
emotional, social, and everyday problems that accompany
memory loss. Sessions were provided twice weekly for one
hour to provide an equivalent amount of social contact.
3. Data Collection
The following measures of psychological and cognitive
functioning were obtained at baseline and after four weeks
of the intervention by trained research assistants who were
blinded to the participant’s group assignment: apathy was
measured using the Apathy Evaluation Scale (AES) [19]. The
AES is an 18-item scale measuring things such as interests,
starting and completing things, and initiating activities.
Internal consistency is good, with an alpha ranging of
0.86–0.94. Depressive symptoms were measured with the
Patient Health Questionnaire (PHQ-9) [25]. The PHQ-9 is
a 9-item scale with scores ≥10 having a sensitivity of 88%
and a specificity of 88% for major depression. The Cornell-
Brown QOL [26] was used to measure quality of life.
Interrater reliability (intraclass r = 0.90) and internal
consistency reliability (Cronbach alpha = 0.81) are very
good. Global cognition was measured with the Mini-Mental
State Examination (MMSE) which consists of 11 simple
questions or tasks. Test-retest reliability is excellent (r >
0.89). Attention and executive functions were measured with
the Trail Making test part B [27] (Table 3). Table 2 displays
evaluation tools used in the study.
3.1. Statistical Methods. Chi-Square tests and t-tests were
used to describe the participants by treatment assignment at
baseline. To determine the impact of the intervention on out-
comes at four weeks, Analysis of Covariance (ANCOVA) was
used. Between group differences are presented and adjusted
for baseline scores. Statistical analyses were performed with
PASW Statistics 18 software. Statistical significance for the
study was established at P < .05.
4. Results
Demographics of the first 77 participants are listed in Table 1.
The control group (structured social support) had an attri-
tion of eighteen participants (37%) after baseline screening
and before the posttest evaluations took place. The treatment
group (mentally stimulating activities) had only one drop-
out thus the groups reported in this paper are uneven with 29
in control and 48 in treatment due to high SS attrition after
intervention assignment. Examining the participants that
remained in the study for four weeks, we found no significant
difference between groups in baseline age, education, apathy,
depression, or MMSE scores. The treatment group had
slightly more depressive symptoms on the PHQ-9, slightly
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Table 2: Variables and measurement.
Cognition and Eligibility
for study
Mini-Mental State examination
(MMSE) [22]
The MMSE consists of 11 simple questions or tasks.
Test-retest reliability (r > 0.89).
Neuropsychiatric behaviors
Clinician administered Apathy
Evaluation Scale (AES) [19]
The AES is an 18-item scale. Internal consistency has an
alpha range of 0.86–0.94.Validity: differences found
P < .05
Quality of life Cornell-Brown QOL [24]
Interrater reliability (intraclass r = 0.90) and internal
consistency reliability (Cronbach alpha = 0.81).
Depression
The Patient Health Questionnaire [25]
(PHQ-9)
Nine-item scale with PHQ-9 score ≥10 had a sensitivity of
88% and a specificity of 88% for major depression.
Executive function Trail Making B [26]
Validity is high, especially when measuring attention and
executive function
Table 3: Analyses of covariance summary table for the effect of treatment.
Adjusted means at baseline Adjusted means at 4 weeks n F Significance (P value)
Apathy
SS 30.38 35.52 29
31.496 <.001
MSA 32.08 28.19 48
Cornell Brown QOL
SS 18.62 20.52 29
4.978 .029
MSA 14.31 22.92 48
MMSE
SS 25.41 24.79 29
22.429 <.001
MSA 25.17 26.10 48
PHQ-9
SS 4.66 6.48 29
13.319 <.001
MSA 5.94 4.55 48
Trail making
SS 192.20 178.89 29
.022 .258 (n.s)
MSA 184.73 161.42 48
more apathy, and slightly poorer quality of life reported on
the Cornell-Brown Scale prior to intervention.
After four weeks of intervention, the participants in the
MSA group had significantly lower apathy scores than those
in the SS group. Specifically, the MSA group dropped 3.9
points on the Apathy Evaluation Scale-Clinical Version and
the SS group increased 5.1 points (P = .001). Quality of
life as measured by the Cornell Brown Scale improved for
both groups but the MSA group was significantly better
(P < .02). The MSA group improved 8.62 points, and the SS
group improved 1.9 points. Participants in the MSA group
improved by .93 on the MMSE (P = .001) and the SS group
declined by .62 indicating a significant improvement in
cognition occurred for the MSA group after removing the
influence of pretest scores. While 57 participants did not
indicate depression diagnosis at baseline, a significant change
occurred in both groups on the PHQ-9 after four weeks.
Participants in the MSA group had a 1.39 point drop, and
the SS group had a 1.82 point increase in depression scores
(P < .001) after removing the influence of pretest scores.
Neither group was significantly different on the Trail Making
test.
5. Discussion
In this four-week study of 77 participants with early-
stage memory loss and apathy, those taking part in the
MSA sessions improved significantly in the areas of apathy,
depressive symptoms, and quality of life in comparison to
those in the structured social support sessions. A small
improvement in mean MMSE score also occurred for the
MSA group but the primary target for this study was apathy.
We did not find any difference in executive function at week
four, but perhaps the intervention will take longer to affect
a change in executive function. These improvements are
consistent with the findings of earlier studies [28, 29]. Our
focus on reducing apathy may provide a novel therapeutic
route to improving mood and quality of life, and maintaining
cognitive function over time. The early-stage support group
experienced a 37% attrition rate, and for those that remained
at the four week posttest, there was a significant increase
in apathy symptoms. These apathy symptoms could explain
poorer performance on the evaluation scales.
Most cognitive stimulation or cognitive training trials
have targeted healthy older adults and have found improve-
ments on specific tasks [30]. This trial took a different
approach with the focus on breaking the pattern of apathy
during early stages of memory loss, which other studies have
shown to lead to premature functional decline. For people
with Alzheimer’s disease, cognitive stimulation therapy that
provides activities involving cognitive processing, within a
social context, with an emphasis on enjoyment holds great
promise.
There were a number of limitations. It should be noted
that this study was limited due to the rigorous inclusion
criteria which were necessary to ensure a homogeneous
group of participants. This meant many participants with
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related neurological conditions and complex health prob-
lems were excluded. Another limitation was the study sites
which were selected by socioeconomic status (SES) (four
high SES and four middle to low SES), which allowed diverse
senior centers with 3–7 candidates to participate. These small
groups enhanced project diversity enrollment but provided
less than ideal program sizes which may have influenced
outcomes. Recruitment and retention in lower SES sites was
a problem. Although groups of 10 were recruited in senior
centers, participants did not attend routinely, preferring to
take part in other activities or simply not attending after
group assignment. Several efforts were made to encourage
participation with phone followups, discussions with family
or staff members at the sites, but the attrition rate for the
control condition was much higher than expected.
In clinical practice, outside of a research trial, partici-
pants and groups would be best selected through clinical
judgment, considering complexities like sensory impair-
ment, communication deficits, interest, and mix of par-
ticipants instead of SES and diversity recruitment. In the
randomization procedure, ideally the generation of the
allocation sequence, enrollment into the trial, and allocation
to group should be separate and performed by different,
independent staff. The PI and Project Director were directly
involved with this process with the statistician due to an
initial budget cut from the trial funder.
Many more people are being diagnosed earlier in the
course of memory loss because of improving sensitivity and
specificity of diagnostic techniques and increased awareness
of Alzheimer’s disease and related disorders. Medical, nurs-
ing, allied health professionals, the Alzheimer’s Association,
and other organizations are responding by offering a range of
support groups to ease the social strains of people with early-
stage dementia. While these support services are needed,
it appears that the MSA cognitive stimulation intervention
program may be another important option for individuals
with early-stage memory changes, especially if they also have
apathy symptoms. Offering this type of cognitive stimulation
could influence the course of the disease overtime as our early
findings show individuals with early-stage memory loss and
apathy perform well, improve, and continue to eagerly attend
twice per week MSA program sessions.
6. Conclusions
Over 70% of people with early-stage Alzheimer’s disease
experience apathy. This symptom is rarely indentified or
treated, which inhibits the older adult’s ability to remain
active with intellectual, interpersonal, and physical activities.
In light of the high prevalence of apathy in dementia and
its impact on quality of life among older people, the use of
MSA cognitive stimulation groups as a means of reducing
apathy and depressive symptoms, as well as increasing quality
of life is very appealing. Therapists, nurses, and other aging
services professionals in community settings can incorporate
classroom style cognitive stimulation sessions for clients with
dementia and apathy who are underperforming or refusing
to participate in other types of therapeutic programs.
Acknowledgments
The authors wish to thank all who kindly participated in the
study in NC, UNCG IRB for compliance review and data
safety monitoring, and Alzheimer’s Association for funding
this study (Grant IIRG-09-131429).
References
[1] L. E. Hebert, P. A. Scherr, J. L. Bienias, D. A. Bennett, and D.
A. Evans, “Alzheimer disease in the US population: prevalence
estimates using the 2000 census,” Archives of Neurology, vol. 60,
no. 8, pp. 1119–1122, 2003.
[2] L. Buettner, S. Fitzsimmons, and S. Atav, “Predicting outcomes
of therapeutic recreation interventions for older adults with
dementia and behavioral symptoms,” Therapeutic Recreation
Journal, vol. 40, no. 1, pp. 33–47, 2006.
[3] K. M. Sink, K. F. Holden, and K. Yaffe, “Pharmacological
treatment of neuropsychiatric symptoms of dementia: a
review of the evidence,” Journal of the American Medical
Association, vol. 293, no. 5, pp. 596–608, 2005.
[4] L. Buettner and S. Fitzsimmons, “Mixed behaviors in demen-
tia: the need for a paradigm shift,” Journal of Gerontological
Nursing, vol. 32, no. 7, pp. 15–22, 2006.
[5] R. S. Marin, “Apathy: a neuropsychiatric syndrome,” Journal
of Neuropsychiatry and Clinical Neurosciences, vol. 3, no. 3, pp.
243–254, 1991.
[6] P. A. Boyle and P. F. Malloy, “Treating apathy in Alzheimer’s
disease,” Dementia and Geriatric Cognitive Disorders, vol. 17,
no. 1-2, pp. 91–99, 2004.
[7] S. E. Starkstein, L. Ingram, M. L. Garau, and R. Mizrahi,
“On the overlap between apathy and depression in dementia,”
Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no.
8, pp. 1070–1074, 2005.
[8] A. M. Landes, S. D. Sperry, M. E. Strauss, and D. S.
Geldmacher, “Apathy in Alzheimer’s disease,” Journal of the
American Geriatrics Society, vol. 49, no. 12, pp. 1700–1707,
2001.
[9] S. E. Starkstein, R. Jorge, R. Mizrahi, and R. G. Robinson,
“A prospective longitudinal study of apathy in Alzheimer’s
disease,” Journal of Neurology, Neurosurgery and Psychiatry,
vol. 77, no. 1, pp. 8–11, 2006.
[10] R. Levy and B. Dubois, “Apathy and the functional anatomy of
the prefrontal cortex-basal ganglia circuits,” Cerebral Cortex,
vol. 16, no. 7, pp. 916–928, 2006.
[11] S. C. Burgener, L. L. Buettner, K. Coen Buckwalter et al.,
“Evidence supporting nutritional interventions for persons in
early stage Alzheimer’s disease (AD),” Journal of Nutrition,
Health and Aging, vol. 12, no. 1, pp. 18–21, 2008.
[12] L. Buettner, “Community-based RT. Peace of mind: a pilot
community-based program for older adults with memory
loss,” Journal of Recreation Therapy, pp. 42–48, 2006.
[13] S. Fitzsimmons and L. L. Buettner, “Therapeutic recreation
interventions for need-driven dementia-compromised behav-
iors in community-dwelling elders,” American Journal of
Alzheimer’s Disease and other Dementias, vol. 17, no. 6, pp.
367–381, 2002.
[14] R. Verkaik, J. C. M. van Weert, and A. L. Francke, “The
effects of psychosocial methods on depressed, aggressive and
apathetic behaviors of people with dementia: a systematic
review,” International Journal of Geriatric Psychiatry, vol. 20,
no. 4, pp. 301–314, 2005.
6 Journal of Aging Research
[15] L. Buettner and S. Fitzsimmons, “Promoting health in
Alzheimer’s disease: evaluation of a 12-week course for people
with early stage dementia,” Journal of Gerontological Nursing.
In press.
[16] A. M. Kolanowski, L. Buettner, D. M. Fick, S. Fitzsimmons,
and M. Cornacchione, “Instituting cognitive rehabilitation in
post-acute care,” Annals of Long-Term Care, vol. 16, no. 2, pp.
40–46, 2008.
[17] R. L. Gould, B. Arroyo, R. G. Brown, A. M. Owen, E. T.
Bullmore, and R. J. Howard, “Brain mechanisms of successful
compensation during learning in Alzheimer disease,” Neurol-
ogy, vol. 67, no. 6, pp. 1011–1017, 2006.
[18] S. I. Rapoport, “Functional brain imaging in the resting state
and during activation in Alzheimer’s disease. Implications
for disease mechanisms involving oxidative phosphorylation,”
Annals of the New York Academy of Sciences, vol. 893, pp. 138–
153, 1999.
[19] R. S. Marin, “Apathy: a neuropsychiatric syndrome,” Journal
of Neuropsychiatry and Clinical Neurosciences, vol. 3, no. 3, pp.
243–254, 1991.
[20] American Psychiatric Association, Diagnostic and Statistical
Manual of Mental Disorders, American Psychiatric Associa-
tion, Washington, DC, USA, 4th edition, 1994.
[21] B. Winblad, K. Palmer, M. Kivipelto et al., “Mild cognitive
impairment—beyond controversies, towards a consensus:
report of the International Working Group on Mild Cognitive
Impairment,” Journal of Internal Medicine, vol. 256, no. 3, pp.
240–246, 2004.
[22] M. F. Folstein, S. E. Folstein, and P. R. McHugh, “‘Mini mental
state’. A practical method for grading the cognitive state of
patients for the clinician,” Journal of Psychiatric Research, vol.
12, no. 3, pp. 189–198, 1975.
[23] S. Fitzsimmons, Brain Fitness, Venture, State College, Pa, USA,
2008.
[24] S. Fitzsimmons, “Brain fitness for older adults with dementia,”
Activities Directors’ Quarterly, vol. 8, no. 2, pp. 36–40, 2007.
[25] R. E. Ready and B. R. Ott, “Quality of life measures for
dementia,” Health and Quality of Life Outcomes, vol. 1, article
no. 11, 2003.
[26] K. Kroenke, R. L. Spitzer, and J. B. W. Williams, “The PHQ-
9: validity of a brief depression severity measure,” Journal of
General Internal Medicine, vol. 16, no. 9, pp. 606–613, 2001.
[27] J. D. Corrigan and N. S. Hinkeldey, “Relationships between
Parts A and B of the Trail Making Test,” Journal of Clinical
Psychology, vol. 43, no. 4, pp. 402–409, 1987.
[28] V. Breuil, J. De Rotrou, F. Forette et al., “Cognitive stimulation
of patients with dementia: preliminary results,” International
Journal of Geriatric Psychiatry, vol. 9, no. 3, pp. 211–217, 1994.
[29] R. T. Woods, “Psychological ‘therapies’ in dementia,” in
Handbook of the Clinical Psychology of Ageing, R. T. Woods,
Ed., pp. 575–600, John Wiley & Sons, Chichester, UK, 1996.
[30] S. L. Willis, S. L. Tennstedt, M. Marsiske et al., “Long-term
effects of cognitive training on everyday functional outcomes
in older adults,” Journal of the American Medical Association,
vol. 296, no. 23, pp. 2805–2814, 2006.
